The kinetics of peripheral blood progenitor cell (PBPC) release induced by G-CSF-alone at 10 g/kg/day were monitored daily in 42 children with solid tumors and leukemias. Median 16-and 27-fold enrichment of circulating CD34
The use of G-CSF-alone to mobilize peripheral blood progenitor cells (PBPCs) has been well documented in normal volunteers [1] [2] [3] and in adult patients with different malignancies. [4] [5] [6] In children, published data of G-CSF use in any indication is limited. In terms of pharmacokinetics, a study with doses ranging from 5 to 15 g/kg/day supported the administration of G-CSF as a single daily subcutaneous (s.c.) dose in most children. 7 As far as the use of G-CSF-alone to mobilize PBPC in paediatric patients is concerned little information is available. 8, 9 We present a prospective study of G-CSF-alone PBPC Correspondence: Dr J Kanold, Service de Pédiatrie B, Hotel Dieu, Centre Hospitalier Universitaire, BP 69, 63000 Clermont-Ferrand Cedex, France Received 6 June 1997; accepted 29 July 1997 mobilization in pediatric patients. The principal goal of this study was to determine the kinetics of progenitor cell release induced by G-CSF at 10 g/kg/day in children in order to optimize the collection program. That is to say, to plan harvest timing to minimize the duration of priming and the number of leukaphereses while maintaining collection efficiency. The efficacy of G-CSF-alone mobilization was evaluated using PBPC peak values and enrichments, collection yields and the engraftment outcome.
Patients and methods

Patients
Forty-two children with different malignancies were referred to our center between January 1994 and June 1996 for collection of PBPCs. There were 30 boys and 12 girls, with ages ranging from 1.5 to 17.5 (median 5) years; 86% were Ͻ10 years old. The median body weight was 18.3 kg (range 10-75). Diagnoses included neuroblastoma 17 patients, rhabdomyosarcoma three patients, lymphomas five patients, brain tumor two patients, germinal cell tumor one patient, acute myeloid leukemia (AML) one patient and acute lymphoblastic leukemia (ALL) 13 patients. The median interval from diagnosis to mobilization was 32 weeks . All patients with solid tumors or lymphomas and the patient with AML were candidates for high-dose chemo-and/or radiotherapy with stem cell rescue (group 1). Children with ALL were high-risk group patients (C group of FRALLE protocol) with no HLA-genoidentical marrow donor for whom back-up collections were performed (group 2). All patients were in complete medullary remission prior to mobilization. Written informed consent was obtained.
PBPC mobilization and collections
In group 1 mobilization started у21 days after the last chemotherapy course. In group 2 mobilization started after 1 week of maintenance treatment (6-mercaptopurine and methotrexate) interruption. No cytokines were given during the week preceding the start of G-CSF. The mobilization regimen was rhG-CSF (Filgrastim; Amgen, Thousand Oaks, CA, USA) 10 g/kg once daily s.c. up to 6 days, started on day 0 at 8 pm and continued every 24 h until the day preceding the last leukapheresis. No dose escalation or reduction was allowed. The kinetics of progenitor cell release were monitored daily from day 0 to the day of the last leukapheresis on blood samples taken at 8 am. Full blood counts, reticulocyte subpopulation counts and progenitor cell count (CD34 + cells, granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst-forming units (BFU-E)) were performed.
Cells were collected 12 h after the preceding dose of G-CSF using a Cobe Spectra continuous-flow blood-cell separator (Cobe, Lakewood, CO, USA) under manual control as describd elsewhere.
10,11
CD34
+ cell determination and in vitro clonogenic assay CD34 + cells were evaluated by direct immunofluorescence with CD34-PE-conjugated MoAb (8G12; HPCA-2; Becton Dickinson, San Jose, CA, USA) using a Cytoron cytometer (Cytoron Absolute; Ortho Diagnostic System, Roissy, France) as described elsewhere. 11 The frequency of clonogenic cells was evaluated using semisolid medium as described elsewhere.
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Transplant regimens
Transplants were performed with PBPCs or with CD34 + PBPCs. Pre-transplant conditioning regimens were in accordance with the disease and dictated by protocols in effect. CD34
+ PBPC were obtained after selection procedure on a Ceprate Stem Cell Concentrator (CellPro, Bothell, WA, USA) as described elsewhere. 11, 12 Patients were maintained in a laminar air flow room during aplastic period. Details of supportive care are described elsewhere. 10 
Efficacy calculation and statistical analysis
Since patients had PBPC collection performed using a target value rather than a fixed number of leukaphereses, it was not possible to use the total number of CD34 + cells or CFU-GM per kg of body weight collected as the dependent variable. Therefore, the total number of progenitor cells per kg bw were divided by the number of patient's blood volumes processed to derive an average yield of progenitor cells per kg bw and per one patient's blood volume processed (1 bvp). The target value of cells to be collected depended on their future therapeutic use (rescue after myeloablative therapy, back-up harvest, in vitro manipulations). In our experience 10 × 10 4 CFU-GM/kg or 2 × 10 6 CD34 + cells/kg are required for safe engraftment and these levels were, therefore, considered to be the minimum graft. The harvest of either one of these target values with no more than two consecutive standard leukaphereses (no more than 5 bvp) was considered as a sufficient collection; in other cases collection was considered as a failure. Correlations were determined using linear regression. The statistical significance was analyzed by Student's t-test. Results were considered significant if P value was р0.05.
Results
PBPC mobilization and cell release kinetics
Baseline white blood cell (WBC) and progenitor cell levels in both groups are shown in Table 1 . As a measure of the mobilization potential, we used the individual peak PBCD34 + cell count. The peak values of PBCD34 + cells ranged from 4 × 10 6 /l to 126 × 10 6 /l. Although 13-fold inter-individual differences were noted in PBCD34
+ cell levels on day 0, the baseline CD34
+ cell blood concentration did not show correlation with the peak PBCD34 + cell count. CFU-GM and BFU-E peak counts were 9.3 × 10 6 /l (range 0.6-39) and 18. 3 10 6 /l (range 1.8-100), respectively. G-CSF priming led to a median 38-fold enrichment of circulating WBC, 16-fold enrichment of PBCD34 + cells, 27-fold and 25-fold enrichments of circulating CFU-GM and BFU-E, respectively. Details of peak values and enrichment are given in Table 1 . No significant differences were observed in progenitor cell enrichment between the two groups of children.
Broad inter-individual variations in progenitor cell levels were observed on each day; up to 15-fold for PBCD34 + cells and up to 400-fold for circulating CFU-GM. The general patterns for mobilization of CD34
+ cells and the clonogenic subsets CFU-GM and BFU-E were similar, with a broad peak occurring after the 3rd to 6th doses of G-CSF (after 4th or 5th dose in 85% of patients). Progenitor cell release kinetics for group 1 are shown in Figure 1 . The same kinetics were observed in group 2.
Individual values of PBCD34 + cell levels in patients from group 1 were not significantly different after the 4th and after the 5th dose of G-CSF.
Baseline CD34 + cell blood concentrations did not show a significant correlation with the number of CD34 + cells in the leukapheresis products. In all patients, the day-ofharvest, PBCD34
+ cell concentration was related to the leukapheresis product CD34 + cell content (r = 0.59, P = 0.0001) and CFU-GM content (r = 0.54, P = 0.0001). No significant correlations were found between progenitor cell enrichment and either patient age, body weight, diagnosis or pre-mobilization treatment duration.
Collections
All collections were performed between after the 3rd and after the 6th dose of G-CSF. The median number of leukaphereses per patient was two (range 1-4) with a total of 4.5 bvp (range 1.8-8.6). The median numbers of cells collected per patient kg were 6. Baseline cell count was performed 12 h before the first G-CSF dose was given to the patient. WBC = white blood cells. carried out both after the 4th and after the 5th dose of G-CSF and as shown in Table 2 no differences were found in the yields of these two collections. The results in Table  3 indicate that at least 2.0 × 10 6 /kg CD34 + cells would be obtained from a single leukapheresis in almost 90% of patients if the PBCD34 + cell concentration is у20 × 10 6 /l. In three patients who had very low levels of circulating progenitor cells during mobilization collections failed; twice in children with ALL and once for a 14-year-old girl with lymphoma.
Tolerance
During G-CSF administration no side-effects were observed; no patient had bone pain or fever and no child required analgesia. No procedure-related complications were encountered during or after the collections.
Engraftment
Nineteen of 29 patients (from group 1 exclusively) received G-CSF-alone primed PBPC (five patients) or PBCD34 + cell grafts (14 patients). The median numbers of infused cells were: 2.9 × 10 6 CD34 + cells (1-10.3) and 13.6 × 10 4 CFU-GM (2.5-103). All patients had successful short-term engraftment even though five patients received Ͻ10 × 10 4 CFU-GM/kg and Ͻ2 × 10 6 CD34 + cell/kg (PBCD34 + cell grafts). The median numbers of days to ANC Ͼ0.5 × 10 9 /l and platelet Ͼ50 × 10 9 /l were 12 (9-40) and 35 (0-54), respectively. Long-term engraftment is evaluable for 12 patients who are alive without medullary relapse or treatment more than 1 year after transplant. They all have normal hematopoiesis. In other children long-term engraftment was not fully evaluable because of relapse followed by chemotherapy treatment or death within 1 year of transplant. 
PBCD34
+ cell levels and LP yields values (median and range) are given for 24 of 29 patients with solid tumors (group 1) for whom collections were performed both after the 4th and after the 5th dose of G-CSF. LP = leukapheresis. Table 3 The day-of-collection PBCD34 + cell concentration and achievement of various target CD34
+ cell collections from a single LP 
Discussion
In children, the kinetics of hematopoietic progenitor cell release induced by G-CSF alone has not been evaluated. Our study was focused on determining mobilization kinetics in children in order to provide data which can be used to plan leukapheresis better and therefore optimize the collection program.
In adults, different protocols of G-CSF administration have been used for mobilization in normal volunteers [1] [2] [3] and patients with malignancies [4] [5] [6] and, as reflected by the yield of PBPC and the time to reach peak levels of circulating progenitor cells, doses of G-CSF between 10 and 16 g/kg/day administered for 4 to 7 days appear to be appropriate.
Based on these data we chose to administrate G-CSF at 10 g/kg for up to 6 days at a single daily dose. Moreover, a once daily subcutaneous injection 12 h before collection offers the possibility of performing the mobilization in out-patients.
In our study the general pattern of progenitor cell mobilization was similar in all children with the peak blood values of circulating progenitor cells occurring after the 4th or the 5th G-CSF administration. The enrichment of the different progenitor types (CD34 + , CFU-GM, BFU-E) was of the same order (16-to 27-fold). In addition, the release of these progenitor types occurred in parallel, correlations were found between peripheral blood levels of CD34 + cells and CFU-GM (r = 0.71, P = 0.00005) and BFU-E (r = 0.63, P = 0.0006). These results are consistent with studies performed with G-CSF-alone in adults. 1 Two observations of note merit consideration: (1) a strong correlation between blood CD34
ϩ cell levels and high fluorescence reticulocyte (HFR) levels (r = 0.7, P = 0.00005). This, easy-to-evaluate parameter may be useful as an early indicator of the circulating progenitor increase during mobilization. (2) In 83% of the children with solid tumors PBCD34
+ cell concentration was not significantly different after the 4th and the 5th dose of G-CSF. This last observation, together with the fact that the yields of these two collections (day 4 and day 5) were the same, have led us to start harvest after the 4th G-CSF administration.
During mobilization, broad inter-individual variations in hematopoietic progenitor cell release were observed. We failed to find a correlation between the PB progenitor cell enrichment and patient age, diagnosis or duration of premobilization treatment. Such inter-individual variations have also been described in normal volunteers 1 indicating that some individuals may be intrinsically poor responders to G-CSF. This may also be the case in children.
In this study, satisfactory progenitor cell collections were achieved despite the relatively small number of blood volumes processed (Ͻ2 bvp for minimum graft). No significant differences were found in collection yields between the two groups of patients. Although the substantial technical differences for measuring CD34 + cells and CFU-GM between institutions make it difficult to use comparative data across studies, the median number of CD34 + cells and CFU-GM collected in this study are comparable with those reported in normal volunteers, 1 adult patients 4 and by Diaz et al 8 in 31 children after G-CSF-alone mobilization. In agreement with some and in contrast with other 8 reports we found a correlation between the collected number of CD34 + cells and CFU-GM (r = 0.48, P = 0.002). As reported by Diaz et al 8 pre-collection patient variables did not affect the collection yields.
Some authors have found that a steady-state 13 or day before collection 14 CD34 + cell concentration in peripheral blood can predict the yield of progenitor cells in the leukapheresis product. Although these data concern adult patients mobilized by chemotherapy plus HGF we were interested in whether a similar analysis could be useful in children. In our study baseline PBCD34
+ cell concentration did not show a significant correlation with the number of CD34 + cells collected. However, we found that the day-ofcollection PBCD34
+ cell concentration was related to the leukapheresis product CD34
+ cell and CFU-GM content and measurement of circulating CD34
+ cells allowed the prediction of harvest magnitude. These results are in agreement with studies with G-CSF-alone in adults 1,14 and Leibundgut et al 15 report a highly significant correlation between the pre-harvest number of circulating CD34
+ cells and the number of CFU-GM in leukapheresis products in 20 children after chemotherapy + HGF mobilization.
We conclude that a mobilization regimen consisting of G-CSF at 10 g/kg for 4 to 5 days with collection of PBPCs starting after the 4th dose is efficient. This technique provides two distinct advantages: (1) a reduction of overall transplantation procedure-related toxicity since there is no mobilization chemotherapy, G-CSF administration is reduced and the number of leukaphereses is minimized; (2) the simple and programmable timing of leukaphereses reducing the psychological impact on the children and allowing the easy integration of the collection in treatment protocols.
